Market News AIOpen the app

Iambic Therapeutics shared early research on its drugs IAM-C1 and IAM217 at the ENA 2026 event.

TrialRead the original at globenewswire.com
Good for IAM

Iambic's candidates showed tumor-fighting activity in early models, and IAM217 has permission to begin a Phase 1/2 study. These are not results in patients, and IAM-C1's trial application is still expected, so the promise remains early.

IAM · Iambic Therapeutics

AI read · Good for IAM

The AI's read

The findings give Iambic early evidence that its drug candidates may work against tumors, including some resistant to existing drugs. IAM217 also has a letter allowing a Phase 1/2 study. The results are from preclinical models, not patients. IAM-C1's trial application is still expected in the fourth quarter of 2026, so neither candidate has yet shown benefits in people.

Get alerts for IAM

Follow Iambic Therapeutics (IAM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IAM
Free on the App Store and Google Play, or on the web.